Loading...

Hangzhou Tigermed Consulting Co., Ltd.

HNGZYPNK
HealthcareMedical - Diagnostics & Research
$4.00
$0.00(0.00%)

Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Stock Overview

Explore Hangzhou Tigermed Consulting Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-10.58%
10.58%
Profit Growth
$0.39
79.99%
EPS Growth
$0.39
79.91%
Operating Margin
7.49%
73.28%
ROE
1.62%
79.99%
Dividend Yield
0.00%
9.28%
Analyst Recommendations data is not available for HNGZYAnalyst Recommendations details for HNGZY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

CEO

Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.

Employees

10,185

Headquarters

F18, Building A – Shengda Science Park, Hangzhou

Founded

2022

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.